S-Ruxolitinib; 941685-37-6; S-Ruxolitinib (INCB018424); Ruxolitinib S enantiomer; (S)-Ruxolitinib; Ruxolitinib (S enantiomer); (3s)-3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]propanenitrile; CHEMBL1287854; (R)-ruxolitinib; (3S)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile; (S)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile; (3S)-3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile (ent-Ruxolitinib); INCB18424; INCB 18424; ruxolitinib-(S); (3S)-3-cyclopentyl-3-(4-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}-1H-pyrazol-1-yl)propanenitrile; SCHEMBL99225; DTXSID30678918; BCP15524; EX-A4005; BDBM50557386; HY-50856A; s2902; ZINC63539381; AKOS005145906; CCG-265007; AC-30902; SW220207-1; F85017; 1H-Pyrazole-1-propanenitrile, beta-cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-, (betaS)-